Elena
Perez Ceballos
Asociado Ciencias de la Salud
![Foto de Elena](/img/uploaded/1a877ce161456762d7c5ac5f7e8268d0.jpeg)
![Foto de Hospital Universitario de Canarias](/img/noimage_org.png)
Hospital Universitario de Canarias
San Cristóbal de La Laguna, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (6)
2023
-
Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study
Cancer Medicine, Vol. 12, Núm. 6, pp. 6536-6546
2017
-
Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma
Cancer Medicine, Vol. 6, Núm. 11, pp. 2507-2514
-
Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin’s lymphoma in patients older than 50 years
Annals of Hematology, Vol. 96, Núm. 1, pp. 9-16
2016
-
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
British Journal of Haematology, Vol. 174, Núm. 6, pp. 859-867
2015
-
The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients
American Journal of Hematology, Vol. 90, Núm. 8, pp. 686-690
2014
-
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial
British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336